An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy

AIDS. 2001 Feb 16;15(3):417-9. doi: 10.1097/00002030-200102160-00017.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use
  • Drug Monitoring*
  • Female
  • HIV Protease Inhibitors / blood
  • HIV Protease Inhibitors / pharmacokinetics*
  • HIV Protease Inhibitors / therapeutic use*
  • HIV-1 / isolation & purification
  • Humans
  • Nelfinavir / blood
  • Nelfinavir / pharmacokinetics*
  • Nelfinavir / therapeutic use*
  • Pregnancy
  • Pregnancy Complications, Infectious / blood
  • Pregnancy Complications, Infectious / drug therapy*
  • Pregnancy Complications, Infectious / virology
  • RNA, Viral / blood
  • Viral Load

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors
  • RNA, Viral
  • Nelfinavir